Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe hypocalcaemia after being given intravenous bisphosphonate.

Literature DB >> 14764499

Severe hypocalcaemia after being given intravenous bisphosphonate.

Rajesh Peter¹, Vinita Mishra, William D Fraser.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2004 PMID： 14764499 PMCID： PMC338107 DOI： 10.1136/bmj.328.7435.335

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

11 in total

1. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.

Authors: E C Sims; P B Rogers; G M Besser; P N Plowman
Journal: Clin Oncol (R Coll Radiol) Date: 1998 Impact factor: 4.126

2. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

Authors: P Major; A Lortholary; J Hon; E Abdi; G Mills; H D Menssen; F Yunus; R Bell; J Body; E Quebe-Fehling; J Seaman
Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544

3. Rehydration in the treatment of severe hypercalcaemia.

Authors: D J Hosking; A Cowley; C A Bucknall
Journal: Q J Med Date: 1981

4. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

Authors: L S Rosen; D Gordon; M Kaminski; A Howell; A Belch; J Mackey; J Apffelstaedt; M Hussein; R E Coleman; D J Reitsma; J J Seaman; B L Chen; Y Ambros
Journal: Cancer J Date: 2001 Sep-Oct Impact factor: 3.360

5. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.

Authors: A Mishra; L Wong; J Jonklaas
Journal: Endocrine Date: 2001-03 Impact factor: 3.633

6. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.

Authors: W D Fraser; F C Logue; S J Gallacher; D S O'Reilly; G H Beastall; S H Ralston; I T Boyle
Journal: Bone Miner Date: 1991-02

7. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.

Authors: H I Harinck; O L Bijvoet; A S Plantingh; J J Body; J W Elte; H P Sleeboom; J Wildiers; J P Neijt
Journal: Am J Med Date: 1987-06 Impact factor: 4.965

8. Symptomatic hypocalcemia after intravenous pamidronate.

Authors: E McIntyre; E Bruera
Journal: J Palliat Care Date: 1996 Impact factor: 2.250

9. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.

Authors: A Cömlekçi; S Biberoglu; Z Hekimsoy; I Okan; O Pişkin; B Sekeroglu; M Alakavuklar
Journal: Intern Med Date: 1998-04 Impact factor: 1.271

10. Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation.

Authors: Joseph R Tucci; Henry G Bone; Guoqin Su; Monique Tan; Zafer E Ozturk; Paul Aftring
Journal: Ther Adv Endocrinol Metab Date: 2015-08 Impact factor: 3.565

Severe hypocalcaemia after being given intravenous bisphosphonate.

1. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.

2. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

3. Rehydration in the treatment of severe hypercalcaemia.

4. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

5. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.

6. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.

7. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.

8. Symptomatic hypocalcemia after intravenous pamidronate.

9. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.

10. Metabolic effects of pamidronate in patients with metastatic bone disease.

1. Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice.

2. Hypocalcaemia after intravenous bisphosphonate: lesson to be learnt.

3. Hypocalcaemia after intravenous bisphosphonate: read the product information first.

Review 4. Drug-induced endocrine and metabolic disorders.

5. Hyperparathyroidism secondary to zoledronic acid infusion: case report.

Review 6. Diagnosis and management of hypocalcaemia.

Review 7. Treatment of osteoporosis in renal insufficiency.

Review 8. Hypocalcemia: updates in diagnosis and management for primary care.

Review 9. Safety of drugs used in the treatment of osteoporosis.

10. Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation.